At least twice as many patients on the approved spesolimab dose maintain improvement in skin symptoms and quality of life ...

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than ...

In this video, Raj Chovatiya, MD, PhD, discusses the latest findings on the use of topical roflumilast in patients with ...

Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis. Among 25 ...

Psoriasis is often considered to be a skin condition, but it’s actually a systemic disease that can lead to symptoms such as ...

1998; Helwig, 2000; Stein, 2000). Psoriasis affects 2% of the U.S. population, accounting for 10% of outpatient visits to dermatologists (Thompson, Feldman, & Fleischer, 1998). In a university ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

See what moon phase it is tonight and find out when you can see the rest of the moon phases for 2025. Today, May 30, 2025, the moon is 3 days old and is in the Waxing Crescent phase of its lunar ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...